J2H-1802
/ J2HBiotech
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 28, 2026
Anti-Psoriatic Effects of J2H-1802, a Mycophenolate Mofetil and 5-Aminosalicylic Acid Hybrid, in an Imiquimod-Induced Psoriasis-like Mouse Model.
(PubMed, Pharmaceutics)
- "In addition, J2H-1802 significantly reduced serum tumor necrosis factor-α (TNF-α) levels and suppressed pro-inflammatory cytokine expression, including IL-1β, IL-6, IL-17, and TNF-α, in psoriatic skin. J2H-1802 alleviates both local and systemic inflammatory features of psoriasis, suggesting its potential as a therapeutic candidate for targeting IL-23/Th17-mediated inflammatory pathways."
Journal • Preclinical • Dermatology • Immunology • Oncology • Psoriasis • Systemic Inflammatory Response Syndrome • IL17A • IL1B • IL23A • IL6 • TNFA
1 to 1
Of
1
Go to page
1